Predictive value of inflammation post-MI attenuated by pravastatin

In the CARE trial, patients experiencing a recurrent coronary event within two years of a myocardial infarction (MI) had higher serum concentrations of C-reactive protein and amyloid A compared to those without an event. Pravastatin attenuated this effect; the risk of a coronary event in patients with evidence of inflammation taking pravastatin (third column) was lower than in those with inflammation taking placebo (fourth column) and was identical to those without evidence of inflammation (first two columns).